Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside

NEW YORK (TheStreet) -- Gilead Sciences (GILD) crushed analysts' bottom line expectations while also beating on revenue estimates, which grew 136% year-over-over. 

This stock sells at just nine times forward estimates, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued on CNBC's "Cramer's Mad Dash" segment. 

The company's drug, Sovaldi, is a cure for hepatitis C, and could go on to be the largest drug of all time, co-host David Faber added. 

Read More: Blue Chip Thursday: Caterpiller, 3M, Ford, GM, Plus Three Homebuilders to Report

Sales for the drug will likely run higher than the suggested $10 billion annual run-rate, Cramer said. 

The company was "very humble" about its results -- perhaps too humble -- and should continue to see long-term growth, as many future patients do not yet realize they have hep. C, Cramer concluded. 

-- Written by Bret Kenwell in Petoskey, Mich.

Read More: Melvin: Wait for Quality and Price to Meet

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition